This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Centers for Medicare and Medicaid Services (CMS) announced on October 13 that it has lifted its coverage limit of one beta-amyloid PETscan per lifetime for patients with Alzheimer’s disease. Medicare coverage decisions for amyloid PETscans will now be made by local Medicare Administrative Contractors (MACs).
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnosticPETscans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnosticPETscans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
Various organizations have applauded the decision by the CMS to remove National Coverage Determination (NCD) limitations to coverage for amyloid PETscans, including the limitation of Medicare or Medicaid coverage to one PETscan per a patient’s lifetime.
tesla MRI AI body composition analysis Cardiac PET Cryo/thermoablation CT colonography Genicular artery embolization Hyperpolarized xenon-129 MRI PET/MRI Photon-counting CT Radiomics Theranostics Whole-body MRI screening Image of the Year 3D PET/MR image. PETscans predict patient response to Pluvicto.
In a study of over 25,000 Medicare beneficiaries with mild cognitive decline or dementia, researchers found that obtaining amyloid positron emission tomography (PET) scans resulted in no statistically significant differences upon subsequent hospitalization and emergency department visit rates at one year.
Details of a False Claims Act complaint filed against the former co-owner of a mobile cardiac PETscan operation are a reminder for providers to avoid financial conflicts with respect to the Physician Self-Referral Law, known as the Stark Law. In a news release , the U.S.
This can only be accomplished with a combination of innovative diagnostic, treatment, and monitoring technology that can enable timely interventions and personalized treatment plans. More accurate diagnostic and monitoring tools can also help manage the high cost of new therapies by preventing the misuse of expensive treatments.
The new criteria expand PET imaging guidance to include tau PET, incorporate updated information, and provide specific guidance to enhance diagnostic precision, treatment decisions, and patient care. This 2024 update is the first revision since the initial AUC for amyloid PET was introduced in 2013. Since then, the U.S.
Recognizing the advent of beta amyloid-targeted therapies for the treatment of Alzheimer’s disease, the Centers for Medicare and Medicaid (CMS) has proposed eliminating coverage restrictions that limit amyloid positron emission tomography (PET) scans to clinical trial participants and one amyloid PETscan per lifetime.
The new criteria expand PET imaging guidance to include tau PET, incorporate updated information, and provide specific guidance to enhance diagnostic precision, treatment decisions, and patient care. This 2024 update is the first revision since the initial AUC for amyloid PET was introduced in 2013. Since then, the U.S.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content